Vaccine-mediated immunity against dengue and the potential for long-term protection against disease

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Slifka, Mark K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antibody; Correlates of immunity; Dengue; Immunological memory; Vaccines

Indexed keywords

CHIMERIVAX; DENGUE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; YFV 17D VACCINE;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; DENGUE; DISEASE COURSE; FLAVIVIRUS INFECTION; HUMAN; IMMUNITY; IMMUNOGENICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEROCONVERSION; SEROPREVALENCE; VACCINATION; VIREMIA; YELLOW FEVER;

EID: 84899995071     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00195     Document Type: Review

References (62)

1. World Health Organisation. Dengue and Dengue Haemorrhagic Fever. Fact sheet No. 117. Geneva: WHO (2014).
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature (2013) 496(7446):504-7. doi: 10.1038/nature12060
3. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science (1988) 239:476-81. doi:10.1126/science.3277268
4. Monath TP. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A (1994) 91(7):2395-400. doi:10.1073/pnas.91.7.2395
5. Thomas SJ, Endy TP. Vaccines for the prevention of dengue: development update. Hum Vaccin (2011) 7(6):674-84.
6. Lam SK. Challenges in reducing dengue burden; diagnostics, control measures and vaccines. Expert Rev Vaccines (2013) 12(9):995-1010. doi:10.1586/14760584.2013.824712
7. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol (2011) 29:587-619. doi:10.1146/annurev-immunol-031210-101315
8. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine (2011) 29(42):7229-41. doi:10.1016/j.vaccine.2011.06.094
9. Coller BA, Clements DE. Dengue vaccines: progress and challenges. Curr Opin Immunol (2011) 23(3):391-8. doi:10.1016/j.coi.2011.03.005
10. Osorio JE, Huang CY, Kinney RM, Stinchcomb DT. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine (2011) 29(42):7251-60. doi:10.1016/j.vaccine.2011.07.020
11. Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine (2011) 29(42):7261-6. doi:10.1016/j.vaccine.2011.07.019
12. Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine (2013) 31(33):3347-52. doi:10.1016/j.vaccine.2013.05.075
13. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet (2012) 380(9853):1559-67. doi:10.1016/S0140-6736(12)61428-7
14. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg (2009) 80(2):302-11.
15. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol (2004) 78(9):4761-75. doi:10.1128/JVI.78.9.4761-4775.2004
16. Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine (2013) 31(41):4501-7. doi:10.1016/j.vaccine.2013.06.079
17. Chokephaibulkit K, Perng GC. Challenges for the formulation of a universal vaccine against dengue. Exp Biol Med (Maywood) (2013) 238(5):566-78. doi:10.1177/1535370212473703
18. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol (2008) 21(2):123-32. doi:10.1089/vim.2008.0007
19. Guirakhoo F, Pugachev K, Arroyo J, Miller C, Zhang ZX, Weltzin R, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology (2002) 298(1):146-59. doi:10.1006/viro.2002.1462
20. Monath TP, Levenbook I, Soike K, Zhang ZX, Ratterree M, Draper K, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol (2000) 74(4):1742-51. doi:10.1128/JVI.74.4.1742-1751.2000
21. Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, et al. The live attenuated chimeric vaccine rWN/DEN4Delta30 is well-tolerated and immunogenic in healthy flavivirus-naive adult volunteers. Vaccine (2013) 31(48):5772-7. doi:10.1016/j.vaccine.2013.07.064
22. Amanna IJ, Slifka MK. Current trends in West Nile virus vaccine development. Expert Rev Vaccines (2014) 13(5):589-608. doi:10.1586/14760584.2014.906309
23. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol (2009) 182(8):4865-73. doi:10.4049/jimmunol.0801974
24. Shrestha B, Diamond MS. Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 78(15):8312-21. doi:10.1128/JVI.78.15.8312-8321.2004
25. Wang Y, Lobigs M, Lee E, Mullbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol (2003) 77(24):13323-34. doi:10.1128/JVI.77.24.13323-13334.2003
26. Brien JD, Uhrlaub JL, Nikolich-Zugich J. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J Immunol (2007) 37(7):1855-63. doi:10.1002/eji.200737196
27. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 6(4):e1000823. doi:10.1371/journal.ppat.1000823
28. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 11(5):522-30. doi:10.1038/nm1240
29. Kyle JL, Balsitis SJ, Zhang L, Beatty PR, Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology (2008) 380(2):296-303. doi:10.1016/j.virol.2008.08.008
30. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A (2010) 107(39):16922-7. doi:10.1073/pnas.1010867107
31. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis (2011) 203(9):1282-91. doi:10.1093/infdis/jir012
32. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, Lyons A, et al. A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine (2011) 29(22):3895-904. doi:10.1016/j.vaccine.2011.03.038
33. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 28(5):710-22. doi:10.1016/j.immuni.2008.02.020
34. Akondy RS, Monson ND, Miller JD, Edupuganti S, Teuwen D, Wu H, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol (2009) 183(12):7919-30. doi:10.4049/jimmunol.0803903
35. James EA, LaFond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol (2013) 87(23):12794-804. doi:10.1128/JVI.01160-13
36. Blom K, Braun M, Ivarsson MA, Gonzalez VD, Falconer K, Moll M, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J Immunol (2013) 190(5):2150-8. doi:10.4049/jimmunol.1202234
37. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A (2013) 110(22):E2046-53. doi:10.1073/pnas.1305227110
38. Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine (2002) 20(7-8):1004-18. doi:10.1016/S0264-410X(01)00457-1
39. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin (2006) 2(2):60-7. doi:10.4161/hv.2.2.2555
40. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol (1998) 56(2):159-67. doi:10.1002/(SICI)1096-9071(199810)56:23.0.CO;2-B
41. Sawyer WA. Persistence of yellow fever immunity. J Prev Med (1931) 5:413-28.
42. Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine (2011) 29(35):6008-16. doi:10.1016/j.vaccine.2011.06.034
43. Thibodeaux BA, Garbino NC, Liss NM, Piper J, Schlesinger JJ, Blair CD, et al. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res (2012) 94(1):1-8. doi:10.1016/j.antiviral.2012.02.001
44. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis (2010) 10(10):712-22. doi:10.1016/S1473-3099(10)70166-3
45. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis (2011) 24(5):442-50. doi:10.1097/QCO.0b013e32834a1b0b
46. Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, et al. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine (2013) 31(23):2603-9. doi:10.1016/j.vaccine.2013.03.038
47. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med (1970) 42(5):311-28.
48. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, et al. Measles antibody: reevaluation of protective titers. J Infect Dis (1990) 162(5):1036-42. doi:10.1093/infdis/162.5.1036
49. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med (2007) 357(19):1903-15. doi:10.1056/NEJMoa066092
50. Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA (2012) 308(20):2126-32. doi:10.1001/jama.2012.14939
51. Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med (2007) 356(11):1121-9. doi:10.1056/NEJMoa064040
52. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis (2010) 201(3):370-7. doi:10.1086/649916
53. Slifka MK, Amanna IJ. How advances in immunology provide insight into improving vaccine efficacy. Vaccine (2014). doi:10.1016/j.vaccine.2014.03.078
54. Niedrig M, Lademann M, Emmerich P, Lafrenz M. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health (1999) 4(12):867-71. doi:10.1046/j.1365-3156.1999.00496.x
55. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ (1981) 59(6):895-900.
56. Bonsignori M, Moody MA, Parks RJ, Holl TM, Kelsoe G, Hicks CB, et al. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 183(4):2708-17. doi:10.4049/jimmunol.0901068
57. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol (1973) 25(4):538-44.
58. Sun W, Eckels KH, Putnak JR, Lyons AG, Thomas SJ, Vaughn DW, et al. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines. J Infect Dis (2013) 207(5):700-8. doi:10.1093/infdis/jis744
59. Thomas SJ. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother (2013) 9(7):1587-90. doi:10.4161/hv.24188
60. Mammen MP, Lyons A, Innis BL, Sun W, McKinney D, Chung RC, et al. Evaluation of dengue virus strains for human challenge studies. Vaccine (2014) 32(13):1488-94. doi:10.1016/j.vaccine.2013.12.040
61. Durbin AP, Whitehead SS. The dengue human challenge model: has the time come to accept this challenge? J Infect Dis (2013) 207(5):697-9. doi:10.1093/infdis/jis749
62. Amanna IJ, Slifka MK. Wanted, dead or alive: new viral vaccines. Antiviral Res (2009) 84(2):119-30. doi:10.1016/j.antiviral.2009.08.008